Eiger Sells Cardiovascular Gene Therapy to Theragene in $18.1M Deal – Pharmaceutical Processing
Pharmaceutical Processing |
Eiger Sells Cardiovascular Gene Therapy to Theragene in $18.1M Deal
Pharmaceutical Processing Eiger BioPharmaceuticals announced an agreement to sell to Theragene Pharmaceuticals, Inc., a private biotechnology company, a non-strategic asset, Mydicar® (rAAV1-SERCA2a). Financial terms of the agreement include a total upfront of $3.1 million in … Eiger sells gene therapy candidate Mydicar to Theragene for $3.1M in cash and stock |
